Does true Gleason pattern 3 merit its cancer descriptor?

Nearly five decades following its conception, the Gleason grading system remains a cornerstone in the prognostication and management of patients with prostate cancer. In the past few years, a debate has been growing whether Gleason score 3 + 3 = 6 prostate cancer is a clinically significant disease. Clinical, molecular and genetic research is addressing the question whether well characterized Gleason score 3 + 3 = 6 disease has the ability to affect the morbidity and quality of life of an individual in whom it is diagnosed. The consequences of treatment of Gleason score 3 + 3 = 6 disease are considerable; few men get through their treatments without sustaining some harm. Further modification of the classification of prostate cancer and dropping the label cancer for Gleason score 3 + 3 = 6 disease might be warranted

Nurses' perceptions of aids and obstacles to the provision of optimal end of life care in ICU

Contains fulltext : 172380.pdf (publisher's version ) (Open Access

Correlation Analysis of Potential BCRP Probes in Different Monolayer Systems

Breast Cancer Resistance Protein (BCRP) is a point of interest in Drug Drug Interaction (DDI) safety testing. Therefore a consensus probe that can be applied as victim in multiple experimental settings is of great benefit. Identification of candidates has been driven by the amount and quality of available clinical data, and as a result sulfasalazine (SSZ) and rosuvastatin (RVS) have been suggested. In this paper the in vitro performance of five possible alternatives is evaluated: atorvastatin (AVS), chlorothiazide (CHT), dantrolene (DAN), topotecan (TPT), and teriflunomide (TRF), and benchmarked against SSZ and RVS in reference in vitro assays for BCRP DDI testing. Based on the results TRF is proposed as an alternate in vitro BCRP probe